• Cisplatin (CDDP) Workflow for Cancer Research

  2026-09-04

  Cisplatin (CDDP) is a practical DNA-damage benchmark for linking cell viability, apoptosis, stemness, and chemotherapy resistance studies. This workflow shows how to prepare fresh material, build interpretable assays, and translate the KLF7–ITGA2 findings in oral cancer into combination and xenograft experiments.

• AMG 487 CXCR3 Antagonist: Workflow Guide

  2026-09-04

  AMG 487 enables controlled dissection of CXCR3-driven chemotaxis, calcium signaling, and macrophage-state transitions. This practical guide connects potency data with assay design, formulation control, and troubleshooting for inflammation and translational biology workflows.

• ARCA EGFP mRNA for Transfection Workflows

  2026-09-03

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for comparing delivery conditions, expression kinetics, and lipid nanoparticle performance in mammalian cells. This practical guide connects reporter-based quality control with synthetic mRNA infection-model workflows, including the experimental logic demonstrated in a recent intestinal-cell study.

• N-octanoyl-L-Homoserine lactone Workflows

  2026-09-03

  Build controlled C8-HSL experiments that connect bacterial quorum sensing with biofilm behavior, virulence, and host-cell signaling. This guide combines concentration-aware assay design, pathway-resolved cancer models, and practical troubleshooting for infection biology research.

• Acridine Orange hydrochloride: Practical Guide

  2026-09-02

  Acridine Orange hydrochloride provides membrane-permeable, differential fluorescence for DNA- and RNA-associated nucleic acid staining in cytochemical, microscopy, and flow-based workflows. It is suitable for cell cycle analysis and apoptosis detection when emission channels, fresh solution preparation, and assay-specific concentration and incubation conditions are validated; it is not intended for non-permeant staining or long-term storage of dye solutions.

• Phosphatase Inhibition for Translational Research

  2026-09-02

  Preserving phosphorylation during sample preparation can strengthen mechanistic interpretation, phosphoproteomic analysis, and translational decision-making. This article connects Phosphatase Inhibitor Cocktail 1 with lessons from heterogeneous BET responses in HPV-positive head and neck cancer.

• GI 254023X: An Assay-First ADAM10 Strategy

  2026-09-01

  GI 254023X is a selective ADAM10 inhibitor suited to mechanistic studies of sheddase-dependent signaling and endothelial barrier injury. This assay-first guide shows how to connect target engagement with Notch1, Jurkat, VE-cadherin, and toxin-challenge readouts without overstating translational evidence.

• NPT1-Mediated Renal Transport of Faropenem

  2026-09-01

  The reference study provided the first molecular evidence that human NPT1, an apical renal inorganic phosphate transporter, also mediates uptake of the organic anion p-aminohippuric acid and several drug-like anions, including faropenem. Its heterologous expression and radiotracer experiments connect NPT1 with renal tubular secretion and offer a mechanistic framework for studying β-lactam disposition, while leaving in vivo clearance and clinical relevance to further investigation.

• Lenalidomide in Myeloma: A Context-Aware Assay Guide

  2026-08-31

  Lenalidomide and CC-5013 are examined through a context-aware framework for multiple myeloma research. This guide connects direct tumor effects, immune restoration, angiogenesis, and DOT1L-dependent innate immune priming to practical assay decisions.

• Oleanolic Acid, FXR, and Cholestatic Liver Injury

  2026-08-31

  The reference study identifies a mechanistic link between oleanolic acid exposure, impaired FXR-regulated bile acid efflux, and disruption of hepatocyte tight junctions. Its combined transporter, barrier-function, and pharmacological-intervention approach clarifies how cholestasis may progress from altered bile handling to structural liver injury.

• WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis

  2026-08-30

  The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic drift in skeletal muscle fibro/adipogenic progenitors. By combining pharmacological inhibition, single-cell profiling, network modeling, and mouse injury models, it connects restoration of β-catenin activity with reduced intramuscular fat accumulation and improved support of muscle satellite cell differentiation.

• MMP-2 Liposomes for Sequential PD-1/IDO Blockade

  2026-08-29

  The reference study develops an MMP-2-responsive, dual-targeting liposome that delivers the PD-1 pathway-blocking peptide AUNP-12 before exposing a tumor-cell-targeting module carrying the IDO inhibitor NLG919. Its sequential design addresses both exhausted T-cell activity and IDO-associated immunosuppression in breast cancer models, providing a useful preclinical framework for combination immunotherapy delivery.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-28

  A 2025 study identifies a previously underappreciated structure–activity relationship in which naturally occurring angiotensin peptides enhance SARS-CoV-2 spike-protein binding to AXL and, for angiotensin IV, to ACE2 and NRP1. Its comparative peptide-design strategy highlights how terminal processing and Tyr4 modification can alter receptor-binding phenotypes, while also showing why these findings require validation beyond biochemical binding assays.

• Tofacitinib Workflows for RA Macrophage Studies

  2026-08-28

  Tofacitinib and CP-690550 provide a practical way to separate cytokine signaling blockade from broader macrophage state changes. This workflow translates RA macrophage findings into concentration-response experiments, phospho-STAT5 measurements, metabolic profiling, and mitochondrial repair assays.

• TAI-1: Hec1 Inhibition and Genome-Stress Assays

  2026-08-27

  TAI-1 is a potent Hec1 inhibitor for investigating mitotic failure, cancer cell proliferation inhibition, and apoptotic cell death induction. This article presents an integrated assay strategy that distinguishes Hec1-driven chromosome misalignment from transcription–replication stress and translates both into stronger preclinical study designs.

8164 records 7/545 page Previous Next First page 上5页 678910 下5页 Last page